nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—CYP2D6—Hydroxyurea—head and neck cancer	0.173	0.228	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Docetaxel—head and neck cancer	0.11	0.144	CbGbCtD
Ondansetron—CYP3A7—Docetaxel—head and neck cancer	0.11	0.144	CbGbCtD
Ondansetron—CYP3A5—Docetaxel—head and neck cancer	0.0825	0.108	CbGbCtD
Ondansetron—CYP1A2—Fluorouracil—head and neck cancer	0.0804	0.106	CbGbCtD
Ondansetron—CYP2C9—Fluorouracil—head and neck cancer	0.0725	0.0952	CbGbCtD
Ondansetron—CYP2D6—Vinblastine—head and neck cancer	0.0614	0.0806	CbGbCtD
Ondansetron—CYP3A4—Vinblastine—head and neck cancer	0.039	0.0513	CbGbCtD
Ondansetron—CYP3A4—Docetaxel—head and neck cancer	0.0322	0.0423	CbGbCtD
Ondansetron—Local reaction—Fluorouracil—head and neck cancer	0.00441	0.0259	CcSEcCtD
Ondansetron—Raised liver function tests—Docetaxel—head and neck cancer	0.00382	0.0224	CcSEcCtD
Ondansetron—Foetor hepaticus—Docetaxel—head and neck cancer	0.00311	0.0183	CcSEcCtD
Ondansetron—Myocardial ischaemia—Fluorouracil—head and neck cancer	0.00304	0.0179	CcSEcCtD
Ondansetron—Hepatic failure—Hydroxyurea—head and neck cancer	0.00274	0.0161	CcSEcCtD
Ondansetron—Supraventricular tachycardia—Docetaxel—head and neck cancer	0.00269	0.0158	CcSEcCtD
Ondansetron—Redness—Docetaxel—head and neck cancer	0.00261	0.0153	CcSEcCtD
Ondansetron—Liver disorder—Docetaxel—head and neck cancer	0.00259	0.0152	CcSEcCtD
Ondansetron—Angina pectoris—Vinblastine—head and neck cancer	0.00227	0.0134	CcSEcCtD
Ondansetron—Myocardial ischaemia—Docetaxel—head and neck cancer	0.00219	0.0129	CcSEcCtD
Ondansetron—Acute coronary syndrome—Vinblastine—head and neck cancer	0.00205	0.0121	CcSEcCtD
Ondansetron—Myocardial infarction—Vinblastine—head and neck cancer	0.00204	0.012	CcSEcCtD
Ondansetron—Swelling—Fluorouracil—head and neck cancer	0.00201	0.0118	CcSEcCtD
Ondansetron—Dysuria—Hydroxyurea—head and neck cancer	0.00199	0.0117	CcSEcCtD
Ondansetron—Drowsiness—Hydroxyurea—head and neck cancer	0.0019	0.0112	CcSEcCtD
Ondansetron—Haemoglobin—Vinblastine—head and neck cancer	0.00188	0.011	CcSEcCtD
Ondansetron—Haemorrhage—Vinblastine—head and neck cancer	0.00187	0.011	CcSEcCtD
Ondansetron—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.0018	0.0105	CcSEcCtD
Ondansetron—Hepatocellular injury—Docetaxel—head and neck cancer	0.00176	0.0104	CcSEcCtD
Ondansetron—Injection site reaction—Docetaxel—head and neck cancer	0.00175	0.0103	CcSEcCtD
Ondansetron—Haemoglobin—Hydroxyurea—head and neck cancer	0.00171	0.0101	CcSEcCtD
Ondansetron—Haemorrhage—Hydroxyurea—head and neck cancer	0.0017	0.01	CcSEcCtD
Ondansetron—Angiopathy—Hydroxyurea—head and neck cancer	0.00155	0.00908	CcSEcCtD
Ondansetron—Chills—Hydroxyurea—head and neck cancer	0.00153	0.00898	CcSEcCtD
Ondansetron—Ill-defined disorder—Vinblastine—head and neck cancer	0.00151	0.00887	CcSEcCtD
Ondansetron—Angina pectoris—Fluorouracil—head and neck cancer	0.00149	0.00877	CcSEcCtD
Ondansetron—Erythema—Hydroxyurea—head and neck cancer	0.00148	0.00872	CcSEcCtD
Ondansetron—Malaise—Vinblastine—head and neck cancer	0.00147	0.00862	CcSEcCtD
Ondansetron—Swelling—Docetaxel—head and neck cancer	0.00145	0.00852	CcSEcCtD
Ondansetron—Hepatic failure—Docetaxel—head and neck cancer	0.00142	0.00837	CcSEcCtD
Ondansetron—Convulsion—Vinblastine—head and neck cancer	0.00141	0.00828	CcSEcCtD
Ondansetron—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.00138	0.00809	CcSEcCtD
Ondansetron—Discomfort—Vinblastine—head and neck cancer	0.00137	0.00804	CcSEcCtD
Ondansetron—Visual disturbance—Docetaxel—head and neck cancer	0.00135	0.00793	CcSEcCtD
Ondansetron—Atrial fibrillation—Docetaxel—head and neck cancer	0.00135	0.00793	CcSEcCtD
Ondansetron—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.00135	0.00791	CcSEcCtD
Ondansetron—Myocardial infarction—Fluorouracil—head and neck cancer	0.00134	0.00787	CcSEcCtD
Ondansetron—Malaise—Hydroxyurea—head and neck cancer	0.00134	0.00786	CcSEcCtD
Ondansetron—Urinary tract infection—Fluorouracil—head and neck cancer	0.00133	0.0078	CcSEcCtD
Ondansetron—Convulsion—Hydroxyurea—head and neck cancer	0.00129	0.00755	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00125	0.00737	CcSEcCtD
Ondansetron—Discomfort—Hydroxyurea—head and neck cancer	0.00125	0.00733	CcSEcCtD
Ondansetron—Haemoglobin—Fluorouracil—head and neck cancer	0.00123	0.00724	CcSEcCtD
Ondansetron—Haemorrhage—Fluorouracil—head and neck cancer	0.00123	0.00721	CcSEcCtD
Ondansetron—Paraesthesia—Vinblastine—head and neck cancer	0.00119	0.007	CcSEcCtD
Ondansetron—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00119	0.00698	CcSEcCtD
Ondansetron—Liver function test abnormal—Docetaxel—head and neck cancer	0.00118	0.00694	CcSEcCtD
Ondansetron—Skin disorder—Hydroxyurea—head and neck cancer	0.00118	0.00691	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.00115	0.00677	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.00115	0.00677	CcSEcCtD
Ondansetron—Pain—Vinblastine—head and neck cancer	0.00114	0.00667	CcSEcCtD
Ondansetron—Constipation—Vinblastine—head and neck cancer	0.00114	0.00667	CcSEcCtD
Ondansetron—Arrhythmia—Fluorouracil—head and neck cancer	0.0011	0.00644	CcSEcCtD
Ondansetron—Feeling abnormal—Vinblastine—head and neck cancer	0.00109	0.00643	CcSEcCtD
Ondansetron—Bronchospasm—Docetaxel—head and neck cancer	0.00109	0.00639	CcSEcCtD
Ondansetron—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00109	0.00638	CcSEcCtD
Ondansetron—Dyspnoea—Hydroxyurea—head and neck cancer	0.00108	0.00634	CcSEcCtD
Ondansetron—Angina pectoris—Docetaxel—head and neck cancer	0.00108	0.00633	CcSEcCtD
Ondansetron—Somnolence—Hydroxyurea—head and neck cancer	0.00108	0.00632	CcSEcCtD
Ondansetron—Erythema—Fluorouracil—head and neck cancer	0.00107	0.00627	CcSEcCtD
Ondansetron—Abdominal pain—Vinblastine—head and neck cancer	0.00105	0.00617	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00105	0.00614	CcSEcCtD
Ondansetron—Fatigue—Hydroxyurea—head and neck cancer	0.00104	0.00613	CcSEcCtD
Ondansetron—Pain—Hydroxyurea—head and neck cancer	0.00104	0.00608	CcSEcCtD
Ondansetron—Constipation—Hydroxyurea—head and neck cancer	0.00104	0.00608	CcSEcCtD
Ondansetron—Vision blurred—Fluorouracil—head and neck cancer	0.00101	0.00591	CcSEcCtD
Ondansetron—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000998	0.00586	CcSEcCtD
Ondansetron—Hypersensitivity—Vinblastine—head and neck cancer	0.000978	0.00575	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000978	0.00574	CcSEcCtD
Ondansetron—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000972	0.00571	CcSEcCtD
Ondansetron—Myocardial infarction—Docetaxel—head and neck cancer	0.000967	0.00568	CcSEcCtD
Ondansetron—Body temperature increased—Hydroxyurea—head and neck cancer	0.000957	0.00562	CcSEcCtD
Ondansetron—Asthenia—Vinblastine—head and neck cancer	0.000953	0.0056	CcSEcCtD
Ondansetron—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000933	0.00548	CcSEcCtD
Ondansetron—Convulsion—Fluorouracil—head and neck cancer	0.000925	0.00544	CcSEcCtD
Ondansetron—Chest pain—Fluorouracil—head and neck cancer	0.000909	0.00534	CcSEcCtD
Ondansetron—Diarrhoea—Vinblastine—head and neck cancer	0.000909	0.00534	CcSEcCtD
Ondansetron—Discomfort—Fluorouracil—head and neck cancer	0.000898	0.00528	CcSEcCtD
Ondansetron—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000892	0.00524	CcSEcCtD
Ondansetron—Haemoglobin—Docetaxel—head and neck cancer	0.00089	0.00523	CcSEcCtD
Ondansetron—Haemorrhage—Docetaxel—head and neck cancer	0.000886	0.0052	CcSEcCtD
Ondansetron—Dizziness—Vinblastine—head and neck cancer	0.000878	0.00516	CcSEcCtD
Ondansetron—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000872	0.00512	CcSEcCtD
Ondansetron—Asthenia—Hydroxyurea—head and neck cancer	0.000869	0.0051	CcSEcCtD
Ondansetron—Nervous system disorder—Fluorouracil—head and neck cancer	0.000855	0.00502	CcSEcCtD
Ondansetron—Visual impairment—Docetaxel—head and neck cancer	0.000853	0.00501	CcSEcCtD
Ondansetron—Tachycardia—Fluorouracil—head and neck cancer	0.000851	0.005	CcSEcCtD
Ondansetron—Vomiting—Vinblastine—head and neck cancer	0.000844	0.00496	CcSEcCtD
Ondansetron—Erythema multiforme—Docetaxel—head and neck cancer	0.000837	0.00492	CcSEcCtD
Ondansetron—Headache—Vinblastine—head and neck cancer	0.000832	0.00489	CcSEcCtD
Ondansetron—Diarrhoea—Hydroxyurea—head and neck cancer	0.000829	0.00487	CcSEcCtD
Ondansetron—Eye disorder—Docetaxel—head and neck cancer	0.000828	0.00486	CcSEcCtD
Ondansetron—Flushing—Docetaxel—head and neck cancer	0.000822	0.00483	CcSEcCtD
Ondansetron—Cardiac disorder—Docetaxel—head and neck cancer	0.000822	0.00483	CcSEcCtD
Ondansetron—Hypotension—Fluorouracil—head and neck cancer	0.000815	0.00478	CcSEcCtD
Ondansetron—Angiopathy—Docetaxel—head and neck cancer	0.000803	0.00472	CcSEcCtD
Ondansetron—Dizziness—Hydroxyurea—head and neck cancer	0.000801	0.0047	CcSEcCtD
Ondansetron—Immune system disorder—Docetaxel—head and neck cancer	0.0008	0.0047	CcSEcCtD
Ondansetron—Mediastinal disorder—Docetaxel—head and neck cancer	0.000798	0.00469	CcSEcCtD
Ondansetron—Chills—Docetaxel—head and neck cancer	0.000795	0.00467	CcSEcCtD
Ondansetron—Arrhythmia—Docetaxel—head and neck cancer	0.000791	0.00465	CcSEcCtD
Ondansetron—Paraesthesia—Fluorouracil—head and neck cancer	0.000783	0.0046	CcSEcCtD
Ondansetron—Dyspnoea—Fluorouracil—head and neck cancer	0.000777	0.00456	CcSEcCtD
Ondansetron—Somnolence—Fluorouracil—head and neck cancer	0.000775	0.00455	CcSEcCtD
Ondansetron—Erythema—Docetaxel—head and neck cancer	0.000771	0.00453	CcSEcCtD
Ondansetron—Vomiting—Hydroxyurea—head and neck cancer	0.00077	0.00452	CcSEcCtD
Ondansetron—Rash—Hydroxyurea—head and neck cancer	0.000764	0.00449	CcSEcCtD
Ondansetron—Dermatitis—Hydroxyurea—head and neck cancer	0.000763	0.00448	CcSEcCtD
Ondansetron—Headache—Hydroxyurea—head and neck cancer	0.000759	0.00446	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000753	0.00442	CcSEcCtD
Ondansetron—Pain—Fluorouracil—head and neck cancer	0.000745	0.00438	CcSEcCtD
Ondansetron—Feeling abnormal—Fluorouracil—head and neck cancer	0.000718	0.00422	CcSEcCtD
Ondansetron—Urticaria—Fluorouracil—head and neck cancer	0.000692	0.00407	CcSEcCtD
Ondansetron—Syncope—Docetaxel—head and neck cancer	0.000691	0.00406	CcSEcCtD
Ondansetron—Body temperature increased—Fluorouracil—head and neck cancer	0.000689	0.00405	CcSEcCtD
Ondansetron—Palpitations—Docetaxel—head and neck cancer	0.000681	0.004	CcSEcCtD
Ondansetron—Loss of consciousness—Docetaxel—head and neck cancer	0.000678	0.00398	CcSEcCtD
Ondansetron—Cough—Docetaxel—head and neck cancer	0.000673	0.00395	CcSEcCtD
Ondansetron—Convulsion—Docetaxel—head and neck cancer	0.000668	0.00392	CcSEcCtD
Ondansetron—Chest pain—Docetaxel—head and neck cancer	0.000656	0.00386	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000652	0.00383	CcSEcCtD
Ondansetron—Hypersensitivity—Fluorouracil—head and neck cancer	0.000642	0.00377	CcSEcCtD
Ondansetron—Dry mouth—Docetaxel—head and neck cancer	0.000642	0.00377	CcSEcCtD
Ondansetron—Anaphylactic shock—Docetaxel—head and neck cancer	0.000629	0.0037	CcSEcCtD
Ondansetron—Shock—Docetaxel—head and neck cancer	0.000619	0.00364	CcSEcCtD
Ondansetron—Nervous system disorder—Docetaxel—head and neck cancer	0.000617	0.00362	CcSEcCtD
Ondansetron—Pruritus—Fluorouracil—head and neck cancer	0.000617	0.00362	CcSEcCtD
Ondansetron—Tachycardia—Docetaxel—head and neck cancer	0.000614	0.00361	CcSEcCtD
Ondansetron—Skin disorder—Docetaxel—head and neck cancer	0.000611	0.00359	CcSEcCtD
Ondansetron—Diarrhoea—Fluorouracil—head and neck cancer	0.000596	0.0035	CcSEcCtD
Ondansetron—Hypotension—Docetaxel—head and neck cancer	0.000588	0.00345	CcSEcCtD
Ondansetron—Dizziness—Fluorouracil—head and neck cancer	0.000576	0.00339	CcSEcCtD
Ondansetron—Paraesthesia—Docetaxel—head and neck cancer	0.000565	0.00332	CcSEcCtD
Ondansetron—Dyspnoea—Docetaxel—head and neck cancer	0.000561	0.00329	CcSEcCtD
Ondansetron—Somnolence—Docetaxel—head and neck cancer	0.000559	0.00329	CcSEcCtD
Ondansetron—Vomiting—Fluorouracil—head and neck cancer	0.000554	0.00326	CcSEcCtD
Ondansetron—Rash—Fluorouracil—head and neck cancer	0.00055	0.00323	CcSEcCtD
Ondansetron—Dermatitis—Fluorouracil—head and neck cancer	0.000549	0.00323	CcSEcCtD
Ondansetron—Headache—Fluorouracil—head and neck cancer	0.000546	0.00321	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000543	0.00319	CcSEcCtD
Ondansetron—Fatigue—Docetaxel—head and neck cancer	0.000542	0.00319	CcSEcCtD
Ondansetron—Pain—Docetaxel—head and neck cancer	0.000538	0.00316	CcSEcCtD
Ondansetron—Constipation—Docetaxel—head and neck cancer	0.000538	0.00316	CcSEcCtD
Ondansetron—Feeling abnormal—Docetaxel—head and neck cancer	0.000518	0.00305	CcSEcCtD
Ondansetron—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000514	0.00302	CcSEcCtD
Ondansetron—Body temperature increased—Docetaxel—head and neck cancer	0.000497	0.00292	CcSEcCtD
Ondansetron—Abdominal pain—Docetaxel—head and neck cancer	0.000497	0.00292	CcSEcCtD
Ondansetron—Hypersensitivity—Docetaxel—head and neck cancer	0.000464	0.00272	CcSEcCtD
Ondansetron—Asthenia—Docetaxel—head and neck cancer	0.000451	0.00265	CcSEcCtD
Ondansetron—Pruritus—Docetaxel—head and neck cancer	0.000445	0.00261	CcSEcCtD
Ondansetron—Diarrhoea—Docetaxel—head and neck cancer	0.00043	0.00253	CcSEcCtD
Ondansetron—Dizziness—Docetaxel—head and neck cancer	0.000416	0.00244	CcSEcCtD
Ondansetron—Vomiting—Docetaxel—head and neck cancer	0.0004	0.00235	CcSEcCtD
Ondansetron—Rash—Docetaxel—head and neck cancer	0.000397	0.00233	CcSEcCtD
Ondansetron—Dermatitis—Docetaxel—head and neck cancer	0.000396	0.00233	CcSEcCtD
Ondansetron—Headache—Docetaxel—head and neck cancer	0.000394	0.00232	CcSEcCtD
Ondansetron—OPRM1—GPCR downstream signaling—KISS1—head and neck cancer	0.000141	0.00206	CbGpPWpGaD
Ondansetron—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.00014	0.00204	CbGpPWpGaD
Ondansetron—CYP2E1—Biological oxidations—GSTM1—head and neck cancer	0.000139	0.00202	CbGpPWpGaD
Ondansetron—CYP3A5—Biological oxidations—GSTM1—head and neck cancer	0.000138	0.00202	CbGpPWpGaD
Ondansetron—CYP2E1—Metapathway biotransformation—GSTM1—head and neck cancer	0.000137	0.002	CbGpPWpGaD
Ondansetron—CYP3A5—Metapathway biotransformation—GSTM1—head and neck cancer	0.000136	0.00199	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—head and neck cancer	0.000135	0.00197	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—GRP—head and neck cancer	0.000132	0.00192	CbGpPWpGaD
Ondansetron—CYP2E1—Biological oxidations—CYP1A1—head and neck cancer	0.000131	0.00192	CbGpPWpGaD
Ondansetron—CYP3A5—Biological oxidations—CYP1A1—head and neck cancer	0.000131	0.00191	CbGpPWpGaD
Ondansetron—CYP3A4—Biological oxidations—NAT2—head and neck cancer	0.00013	0.0019	CbGpPWpGaD
Ondansetron—CYP2E1—Metapathway biotransformation—CYP1A1—head and neck cancer	0.00013	0.00189	CbGpPWpGaD
Ondansetron—CYP3A5—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000129	0.00189	CbGpPWpGaD
Ondansetron—CYP3A4—Metapathway biotransformation—NAT2—head and neck cancer	0.000128	0.00187	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—KISS1—head and neck cancer	0.000128	0.00187	CbGpPWpGaD
Ondansetron—CYP1A2—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000126	0.00184	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—head and neck cancer	0.000125	0.00183	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—KISS1—head and neck cancer	0.000122	0.00178	CbGpPWpGaD
Ondansetron—OPRM1—TCR Signaling Pathway—HRAS—head and neck cancer	0.00012	0.00175	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—GRP—head and neck cancer	0.00012	0.00175	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—GRP—head and neck cancer	0.000116	0.0017	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—UROD—head and neck cancer	0.000116	0.00169	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—UROD—head and neck cancer	0.000115	0.00168	CbGpPWpGaD
Ondansetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000115	0.00167	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—KISS1—head and neck cancer	0.000111	0.00162	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—head and neck cancer	0.000106	0.00155	CbGpPWpGaD
Ondansetron—OPRM1—TCR Signaling Pathway—AKT1—head and neck cancer	0.000106	0.00154	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—GRP—head and neck cancer	0.000106	0.00154	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—GRP—head and neck cancer	0.0001	0.00147	CbGpPWpGaD
Ondansetron—CYP2D6—Biological oxidations—GSTM1—head and neck cancer	9.84e-05	0.00144	CbGpPWpGaD
Ondansetron—CYP2C9—Biological oxidations—GSTM1—head and neck cancer	9.75e-05	0.00142	CbGpPWpGaD
Ondansetron—CYP2D6—Metapathway biotransformation—GSTM1—head and neck cancer	9.7e-05	0.00142	CbGpPWpGaD
Ondansetron—CYP2C9—Metapathway biotransformation—GSTM1—head and neck cancer	9.62e-05	0.0014	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—head and neck cancer	9.57e-05	0.0014	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—head and neck cancer	9.57e-05	0.0014	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—head and neck cancer	9.57e-05	0.0014	CbGpPWpGaD
Ondansetron—CYP2D6—Biological oxidations—CYP1A1—head and neck cancer	9.33e-05	0.00136	CbGpPWpGaD
Ondansetron—CYP2C9—Biological oxidations—CYP1A1—head and neck cancer	9.24e-05	0.00135	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—VEGFA—head and neck cancer	9.22e-05	0.00135	CbGpPWpGaD
Ondansetron—CYP2D6—Metapathway biotransformation—CYP1A1—head and neck cancer	9.2e-05	0.00134	CbGpPWpGaD
Ondansetron—CYP2C9—Metapathway biotransformation—CYP1A1—head and neck cancer	9.12e-05	0.00133	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—GRP—head and neck cancer	9.12e-05	0.00133	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—KISS1—head and neck cancer	8.59e-05	0.00125	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—IL2—head and neck cancer	8.41e-05	0.00123	CbGpPWpGaD
Ondansetron—CYP1A2—Biological oxidations—GSTM1—head and neck cancer	8.33e-05	0.00122	CbGpPWpGaD
Ondansetron—KCNH2—Neuronal System—MAPK1—head and neck cancer	8.31e-05	0.00121	CbGpPWpGaD
Ondansetron—CYP1A2—Metapathway biotransformation—GSTM1—head and neck cancer	8.22e-05	0.0012	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—UROD—head and neck cancer	8.2e-05	0.0012	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—UROD—head and neck cancer	8.13e-05	0.00119	CbGpPWpGaD
Ondansetron—CYP1A2—Biological oxidations—CYP1A1—head and neck cancer	7.9e-05	0.00115	CbGpPWpGaD
Ondansetron—CYP1A2—Metapathway biotransformation—CYP1A1—head and neck cancer	7.79e-05	0.00114	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—head and neck cancer	7.68e-05	0.00112	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—IL2—head and neck cancer	7.63e-05	0.00111	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—KISS1—head and neck cancer	7.58e-05	0.00111	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—GRP—head and neck cancer	7.07e-05	0.00103	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—UROD—head and neck cancer	6.95e-05	0.00101	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—STAT6—head and neck cancer	6.86e-05	0.001	CbGpPWpGaD
Ondansetron—KCNH2—Neuronal System—HRAS—head and neck cancer	6.67e-05	0.000974	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—NAT2—head and neck cancer	6.63e-05	0.000967	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—NOTCH1—head and neck cancer	6.55e-05	0.000956	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KISS1—head and neck cancer	6.54e-05	0.000954	CbGpPWpGaD
Ondansetron—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	6.43e-05	0.000939	CbGpPWpGaD
Ondansetron—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	6.34e-05	0.000926	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	6.31e-05	0.000921	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—GRP—head and neck cancer	6.24e-05	0.000911	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—MAPK3—head and neck cancer	6.14e-05	0.000896	CbGpPWpGaD
Ondansetron—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	6.1e-05	0.00089	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—YAP1—head and neck cancer	6.07e-05	0.000886	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—STAT6—head and neck cancer	6.06e-05	0.000884	CbGpPWpGaD
Ondansetron—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	6.01e-05	0.000877	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—MAPK1—head and neck cancer	5.84e-05	0.000852	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—EGFR—head and neck cancer	5.84e-05	0.000852	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—DPYD—head and neck cancer	5.81e-05	0.000848	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—PIK3CA—head and neck cancer	5.58e-05	0.000814	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—YAP1—head and neck cancer	5.51e-05	0.000805	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	5.39e-05	0.000787	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—GRP—head and neck cancer	5.39e-05	0.000786	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—UROD—head and neck cancer	5.36e-05	0.000783	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—YAP1—head and neck cancer	5.36e-05	0.000782	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—STAT6—head and neck cancer	5.23e-05	0.000763	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—PIK3CA—head and neck cancer	5.07e-05	0.000739	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—NAT2—head and neck cancer	4.8e-05	0.0007	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—NAT2—head and neck cancer	4.79e-05	0.000699	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—HRAS—head and neck cancer	4.69e-05	0.000684	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—YAP1—head and neck cancer	4.63e-05	0.000675	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—AKT1—head and neck cancer	4.56e-05	0.000665	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—IL2—head and neck cancer	4.51e-05	0.000658	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CCND1—head and neck cancer	4.4e-05	0.000641	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—PTEN—head and neck cancer	4.24e-05	0.000619	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—DPYD—head and neck cancer	4.21e-05	0.000614	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—DPYD—head and neck cancer	4.2e-05	0.000613	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—AKT1—head and neck cancer	4.14e-05	0.000604	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—YAP1—head and neck cancer	3.99e-05	0.000583	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—YAP1—head and neck cancer	3.99e-05	0.000582	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—VEGFA—head and neck cancer	3.83e-05	0.000559	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—STAT3—head and neck cancer	3.79e-05	0.000554	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—MAPK3—head and neck cancer	3.63e-05	0.000529	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	3.59e-05	0.000523	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	3.55e-05	0.000518	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—IL2—head and neck cancer	3.51e-05	0.000512	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—MAPK1—head and neck cancer	3.45e-05	0.000503	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—EGFR—head and neck cancer	3.45e-05	0.000503	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—NAT2—head and neck cancer	3.41e-05	0.000497	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—NAT2—head and neck cancer	3.38e-05	0.000493	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—TYMS—head and neck cancer	3.31e-05	0.000483	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—GSTM1—head and neck cancer	3.27e-05	0.000478	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—IL2—head and neck cancer	3.19e-05	0.000465	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—GPX1—head and neck cancer	3.13e-05	0.000457	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—CYP1A1—head and neck cancer	3.1e-05	0.000453	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—IL2—head and neck cancer	3.1e-05	0.000452	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	3.06e-05	0.000447	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	3.03e-05	0.000443	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—PIK3CA—head and neck cancer	2.99e-05	0.000437	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—DPYD—head and neck cancer	2.99e-05	0.000436	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—DPYD—head and neck cancer	2.96e-05	0.000432	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—TP53—head and neck cancer	2.9e-05	0.000423	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—NAT2—head and neck cancer	2.89e-05	0.000421	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—YAP1—head and neck cancer	2.83e-05	0.000414	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—IL2—head and neck cancer	2.81e-05	0.000411	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—YAP1—head and neck cancer	2.81e-05	0.00041	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—HRAS—head and neck cancer	2.77e-05	0.000404	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NOTCH1—head and neck cancer	2.74e-05	0.000399	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—IL2—head and neck cancer	2.68e-05	0.00039	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—MAPK3—head and neck cancer	2.56e-05	0.000374	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—DPYD—head and neck cancer	2.53e-05	0.000369	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—AKT1—head and neck cancer	2.45e-05	0.000357	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—MAPK1—head and neck cancer	2.44e-05	0.000356	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—EGFR—head and neck cancer	2.44e-05	0.000356	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—IL2—head and neck cancer	2.43e-05	0.000355	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NOTCH1—head and neck cancer	2.42e-05	0.000353	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—YAP1—head and neck cancer	2.4e-05	0.00035	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—TYMS—head and neck cancer	2.4e-05	0.00035	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—TYMS—head and neck cancer	2.39e-05	0.000349	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GSTM1—head and neck cancer	2.37e-05	0.000346	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GSTM1—head and neck cancer	2.37e-05	0.000345	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—PIK3CA—head and neck cancer	2.33e-05	0.00034	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GPX1—head and neck cancer	2.27e-05	0.000331	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GPX1—head and neck cancer	2.27e-05	0.000331	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—MAPK3—head and neck cancer	2.26e-05	0.00033	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CYP1A1—head and neck cancer	2.25e-05	0.000328	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CYP1A1—head and neck cancer	2.24e-05	0.000327	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NAT2—head and neck cancer	2.23e-05	0.000325	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—MAPK1—head and neck cancer	2.15e-05	0.000314	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—EGFR—head and neck cancer	2.15e-05	0.000314	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—PIK3CA—head and neck cancer	2.12e-05	0.000309	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	2.11e-05	0.000308	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NOTCH1—head and neck cancer	2.09e-05	0.000304	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—PIK3CA—head and neck cancer	2.06e-05	0.0003	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—HRAS—head and neck cancer	1.96e-05	0.000286	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—MAPK3—head and neck cancer	1.95e-05	0.000285	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—DPYD—head and neck cancer	1.95e-05	0.000285	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—AKT1—head and neck cancer	1.9e-05	0.000278	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IL2—head and neck cancer	1.88e-05	0.000275	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—PIK3CA—head and neck cancer	1.87e-05	0.000273	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—MAPK1—head and neck cancer	1.86e-05	0.000271	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—EGFR—head and neck cancer	1.86e-05	0.000271	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—YAP1—head and neck cancer	1.85e-05	0.00027	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PTGS2—head and neck cancer	1.85e-05	0.000269	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.84e-05	0.000269	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CCND1—head and neck cancer	1.84e-05	0.000268	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.8e-05	0.000263	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—PIK3CA—head and neck cancer	1.78e-05	0.000259	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PTEN—head and neck cancer	1.77e-05	0.000259	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—AKT1—head and neck cancer	1.73e-05	0.000252	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—HRAS—head and neck cancer	1.73e-05	0.000252	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—TYMS—head and neck cancer	1.7e-05	0.000248	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—TYMS—head and neck cancer	1.69e-05	0.000246	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GSTM1—head and neck cancer	1.68e-05	0.000245	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—AKT1—head and neck cancer	1.68e-05	0.000245	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GSTM1—head and neck cancer	1.67e-05	0.000243	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IL2—head and neck cancer	1.66e-05	0.000243	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CCND1—head and neck cancer	1.62e-05	0.000237	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—PIK3CA—head and neck cancer	1.61e-05	0.000235	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GPX1—head and neck cancer	1.61e-05	0.000235	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PTEN—head and neck cancer	1.61e-05	0.000235	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—VEGFA—head and neck cancer	1.6e-05	0.000234	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GPX1—head and neck cancer	1.6e-05	0.000233	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CYP1A1—head and neck cancer	1.59e-05	0.000233	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—STAT3—head and neck cancer	1.59e-05	0.000231	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CYP1A1—head and neck cancer	1.58e-05	0.000231	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.57e-05	0.00023	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PTEN—head and neck cancer	1.56e-05	0.000228	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—AKT1—head and neck cancer	1.53e-05	0.000223	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MAPK3—head and neck cancer	1.51e-05	0.000221	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—HRAS—head and neck cancer	1.49e-05	0.000218	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—AKT1—head and neck cancer	1.45e-05	0.000212	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—TYMS—head and neck cancer	1.44e-05	0.00021	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MAPK1—head and neck cancer	1.44e-05	0.00021	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—EGFR—head and neck cancer	1.44e-05	0.00021	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IL2—head and neck cancer	1.44e-05	0.000209	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GSTM1—head and neck cancer	1.43e-05	0.000208	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—VEGFA—head and neck cancer	1.41e-05	0.000206	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—STAT3—head and neck cancer	1.4e-05	0.000204	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CCND1—head and neck cancer	1.4e-05	0.000204	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GPX1—head and neck cancer	1.36e-05	0.000199	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CYP1A1—head and neck cancer	1.35e-05	0.000197	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PTEN—head and neck cancer	1.35e-05	0.000197	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MAPK3—head and neck cancer	1.34e-05	0.000195	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PTGS2—head and neck cancer	1.34e-05	0.000195	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PTGS2—head and neck cancer	1.33e-05	0.000195	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—AKT1—head and neck cancer	1.32e-05	0.000192	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.3e-05	0.00019	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MAPK1—head and neck cancer	1.27e-05	0.000186	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—EGFR—head and neck cancer	1.27e-05	0.000186	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PIK3CA—head and neck cancer	1.25e-05	0.000182	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—VEGFA—head and neck cancer	1.22e-05	0.000178	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TP53—head and neck cancer	1.21e-05	0.000177	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—STAT3—head and neck cancer	1.21e-05	0.000176	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PTEN—head and neck cancer	1.17e-05	0.00017	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PTEN—head and neck cancer	1.16e-05	0.00017	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—HRAS—head and neck cancer	1.16e-05	0.000169	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MAPK3—head and neck cancer	1.15e-05	0.000168	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CA—head and neck cancer	1.14e-05	0.000166	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—TYMS—head and neck cancer	1.11e-05	0.000162	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.11e-05	0.000162	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CA—head and neck cancer	1.1e-05	0.000161	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTM1—head and neck cancer	1.1e-05	0.000161	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MAPK1—head and neck cancer	1.1e-05	0.00016	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—EGFR—head and neck cancer	1.1e-05	0.00016	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TP53—head and neck cancer	1.07e-05	0.000156	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GPX1—head and neck cancer	1.05e-05	0.000154	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP1A1—head and neck cancer	1.04e-05	0.000152	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—AKT1—head and neck cancer	1.02e-05	0.000149	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HRAS—head and neck cancer	1.02e-05	0.000149	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CA—head and neck cancer	9.53e-06	0.000139	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PTGS2—head and neck cancer	9.48e-06	0.000138	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PTGS2—head and neck cancer	9.4e-06	0.000137	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—AKT1—head and neck cancer	9.27e-06	0.000135	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TP53—head and neck cancer	9.22e-06	0.000134	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—AKT1—head and neck cancer	9.02e-06	0.000132	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HRAS—head and neck cancer	8.81e-06	0.000129	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PTEN—head and neck cancer	8.27e-06	0.000121	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CA—head and neck cancer	8.22e-06	0.00012	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CA—head and neck cancer	8.21e-06	0.00012	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PTEN—head and neck cancer	8.2e-06	0.00012	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PTGS2—head and neck cancer	8.03e-06	0.000117	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—AKT1—head and neck cancer	7.78e-06	0.000114	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PTEN—head and neck cancer	7.01e-06	0.000102	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—AKT1—head and neck cancer	6.72e-06	9.8e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—AKT1—head and neck cancer	6.7e-06	9.78e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTGS2—head and neck cancer	6.2e-06	9.05e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CA—head and neck cancer	5.83e-06	8.51e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CA—head and neck cancer	5.78e-06	8.44e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTEN—head and neck cancer	5.41e-06	7.89e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CA—head and neck cancer	4.94e-06	7.21e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—AKT1—head and neck cancer	4.77e-06	6.96e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—AKT1—head and neck cancer	4.73e-06	6.9e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—AKT1—head and neck cancer	4.04e-06	5.89e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CA—head and neck cancer	3.81e-06	5.57e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—AKT1—head and neck cancer	3.12e-06	4.55e-05	CbGpPWpGaD
